XML 21 R12.htm IDEA: XBRL DOCUMENT v3.25.3
Shareholders' Equity
 9 Months Ended
Sep. 28, 2025
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
Earnings per Share
The following table sets forth the computation of basic and diluted earnings per share:
Three Months EndedNine Months Ended
September 28, 2025September 29, 2024September 28, 2025September 29, 2024
Numerator:
Net income from continuing operations$123,065 $31,391 $241,033 $124,314 
Net (income)/loss from continuing operations attributable to noncontrolling interests(147)(241)17 (399)
Net income from continuing operations attributable to Sonoco$122,918 $31,150 $241,050 $123,915 
Net income attributable to Sonoco$122,918 $50,921 $670,770 $206,909 
Denominator:
Weighted average common shares outstanding:
Basic99,182 98,683 99,098 98,616 
Dilutive effect of shared-based compensation466 584 421 605 
Diluted 99,648 99,267 99,519 99,221 
Per common share:
Basic earnings per common share:
Net income from continuing operations$1.24 $0.32 $2.43 $1.26 
Net income attributable to Sonoco$1.24 $0.52 $6.77 $2.10 
Diluted earnings per common share:
Net income from continuing operations$1.23 $0.31 $2.42 $1.25 
Net income attributable to Sonoco$1.23 $0.51 $6.74 $2.09 
Cash dividends$0.53 $0.52 $1.58 $1.55 
No adjustments were made to “Net income attributable to Sonoco” in the computations of net income attributable to Sonoco per common share.
Anti-dilutive Securities
Potentially dilutive securities are calculated in accordance with the treasury stock method, which assumes the proceeds from the exercise of all dilutive stock appreciation rights (“SARs”) are used to repurchase the Company’s common stock. Certain SARs are not dilutive because either the exercise price is greater than the average market price of the stock during the reporting period or assumed repurchases from proceeds from the exercise of the SARs were anti-dilutive. These SARs may become dilutive in the future if the market price of the Company’s common stock appreciates.
The average numbers of SARs that were anti-dilutive and, therefore, not included in the computation of diluted earnings per share during the three- and nine-month periods ended September 28, 2025 and September 29, 2024 were as follows (in thousands):
Three Months EndedNine Months Ended
September 28, 2025September 29, 2024September 28, 2025September 29, 2024
Anti-dilutive stock appreciation rights496 455 520 378 
Stock Repurchases
On April 20, 2021, the Company’s Board of Directors (the “Board”) authorized the repurchase of the Company’s common stock in an aggregate amount of up to $350,000. Following several repurchase transactions in 2021, a total of $137,972 remained available for share repurchases under this authorization as of December 31, 2021. Subsequent to 2021, no additional shares have been repurchased under this authorization.
The Company regularly repurchases shares of its common stock to satisfy employee tax withholding obligations in association with certain share-based compensation awards. These repurchases, which are not part of a publicly announced plan or program, totaled 220 shares during the nine-month period ended September 28, 2025, at a cost of $10,580, and 163 shares during the nine-month period ended September 29, 2024, at a cost of $9,172.
Dividend Declarations
On February 12, 2025, the Board declared a regular quarterly dividend of $0.52 per share. This dividend was paid on March 10, 2025 to all shareholders of record as of February 26, 2025.
On April 16, 2025, the Board declared a regular quarterly dividend of $0.53 per share. This dividend was paid on
June 10, 2025 to all shareholders of record as of May 9, 2025.
On July 16, 2025, the Board declared a regular quarterly dividend of $0.53 per share. This dividend is payable on September 10, 2025 to all shareholders of record as of August 8, 2025.
On October 14, 2025, subsequent to the end of the quarter, the Board declared a regular quarterly dividend of $0.53 per share. This dividend is payable on December 10, 2025 to all shareholders of record as of November 10, 2025.